See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Donald Trump
Baseball
Nintendo
Natural Disasters
Social Media
European Union
Trade War
Republican Party
Taxes
Democratic Party
Senate
Published • loading... • Updated

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 – Optimum Strategic CommunicationsLink to: Weekly round-up: Optimum celebrates innovation from industry awards to breakthrough treatmentsScroll to top

Summary by Optimum Strategic Communications
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
AACR Meeting NewsAACR Meeting News

AACR CEO Margaret Foti, PhD, MD (hc), invites you to the 2025 Annual Meeting of the American Association for Cancer Research - AACR Annual Meeting News

Margaret Foti, PhD, MD (hc) The American Association for Cancer Research (AACR) looks forward to hosting the AACR Annual Meeting 2025, April 25-30, in Chicago, Illinois. As the touchstone of the cancer research community, the AACR Annual Meeting is the place where science and medicine come together—where cancer scientists, clinicians, other healthcare professionals, survivors, and patient advocates gather to discuss the latest breakthroughs, mak…

Read Full Article
Optimum Strategic CommunicationsOptimum Strategic Communications

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 – Optimum Strategic CommunicationsLink to: Weekly round-up: Optimum celebrates innovation from industry awards to breakthrough treatmentsScroll to top

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Optimum Strategic Communications broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Innovation

Innovation

Strasbourg

Strasbourg

Maryland

Maryland

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal